Status:

Red

Decision Date:

March 2021

Comments

NICE TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis. ICB commissioned.

NICE TA792 - Filgotinib for treating moderately to severely active ulcerative colitis. ICB commissioned. (Decision date - July 2022)

 

 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again